InvestorsHub Logo
icon url

ggwpq

08/09/14 1:32 PM

#32002 RE: redlyon #32000

Red, no mention of Cardio background for Jenkins:

Biography for John
K.
Jenkins, M.D.
Dr. Jenkins is currently the Director of the Office of New Drugs, Center for Drug
Evaluation and Research, Food and Drug Administration. Dr. Jenkins received his
undergraduate degree in biology from East Tennessee State University in 1979 and his
medical degree from the University of Tennessee at Memphis in 1983. Dr. Jenkins
completed his postgraduate medical training in internal medicine, pulmonary disease, and
critical care medicine at Virginia Commonwealth University/Medical College of Virginia
from 1983 until 1988. Dr. Jenkins is Board Certified in Internal Medicine and Pulmonary
Diseases by the American Board of Internal Medicine. Following completion of his
medical training, Dr. Jenkins joined the faculty of MCV as an Assistant Professor of
Pulmonary and Critical Care Medicine and as a Staff Physician at the McGuire VA
Medical Center in Richmond. Dr. Jenkins joined FDA as a medical officer in the
Division of Oncology and Pulmonary Drug Products in 1992. He subsequently served as
Pulmonary Medical Group Leader and Acting Division Director before being appointed
as Director of the newly created Division of Pulmonary Drug Products in 1995. Dr.
Jenkins became the Director of the Office of Drug Evaluation II in 1999 and served in
that position until he was appointed to his current position in January 2002.
icon url

Biobillionair

08/10/14 12:13 AM

#32010 RE: redlyon #32000

Red,
Great post! But.....Rachel Sherman/Berhman .....Berhman Capital...Athrotech...Omthera...is still on the hook for $2Billion in Market Damages to Amarin and Stakeholders....if you want details I'll post them...otherwise don't Fck with me.

BB